

Turner, Sharon

ENTERED



1600

#13

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/724,552

DATE: 01/27/2003

TIME: 09:35:56

RECEIVED

JAN 30 2003

Input Set : N:\Crif3\RULE60\09724552.raw.txt
 Output Set: N:\CRF4\01272003\I724552.raw

TECH CENTER 1600/2900

1 <110> APPLICANT: Schenk, Dale B.
 2 Neuralab Limited
 3 <120> TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
 4 <130> FILE REFERENCE: 15270J-004740US
 5 <140> CURRENT APPLICATION NUMBER: US/09/724,552
 6 <141> CURRENT FILING DATE: 2000-11-28
 7 <150> PRIOR APPLICATION NUMBER: US/09/580,019A
 8 <151> PRIOR FILING DATE: 2000-05-26
 9 <150> PRIOR APPLICATION NUMBER: 09/322,289
 10 <151> PRIOR FILING DATE: 1999-05-28
 11 <160> NUMBER OF SEQ ID NOS: 5
 12 <170> SOFTWARE: PatentIn Ver. 2.1
 14 <210> SEQ ID NO: 1
 15 <211> LENGTH: 42
 16 <212> TYPE: PRT
 17 <213> ORGANISM: Homo sapiens
 18 <220> FEATURE:
 19 <223> OTHER INFORMATION: human Abeta42 beta-amyloid peptide
 20 <400> SEQUENCE: 1
 21 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
 22 1 5 10 15
 23 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
 24 20 25 30
 25 Gly Leu Met Val Gly Gly Val Val Ile Ala
 26 35 40
 28 <210> SEQ ID NO: 2
 29 <211> LENGTH: 13
 30 <212> TYPE: PRT
 31 <213> ORGANISM: Artificial Sequence
 32 <220> FEATURE:
 33 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta1-12
 34 peptide with carboxyl terminal Cys residue
 35 inserted
 36 <400> SEQUENCE: 2
 37 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Cys
 38 1 5 10
 40 <210> SEQ ID NO: 3
 41 <211> LENGTH: 6
 42 <212> TYPE: PRT
 43 <213> ORGANISM: Artificial Sequence
 44 <220> FEATURE:
 45 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta1-5
 46 peptide with carboxyl terminal Cys residue

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/724,552

DATE: 01/27/2003

TIME: 09:35:56

Input Set : N:\Crif3\RULE60\09724552.raw.txt
Output Set: N:\CRF4\01272003\I724552.raw

```

47      inserted
48 <400> SEQUENCE: 3
49      Asp Ala Glu Phe Arg Cys
50          1             5
52 <210> SEQ ID NO: 4
53 <211> LENGTH: 12
54 <212> TYPE: PRT
55 <213> ORGANISM: Artificial Sequence
56 <220> FEATURE:
57 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta33-42
58      peptide with carboxyl terminal Cys residue
59      inserted
60 <220> FEATURE:
61 <221> NAME/KEY: MOD_RES
62 <222> LOCATION: (2)
63 <223> OTHER INFORMATION: Xaa = amino heptanoic acid
64 <400> SEQUENCE: 4
W--> 65      Cys Xaa Gly Leu Met Val Gly Gly Val Val Ile Ala
66          1             5             10
68 <210> SEQ ID NO: 5
69 <211> LENGTH: 19
70 <212> TYPE: PRT
71 <213> ORGANISM: Artificial Sequence
72 <220> FEATURE:
73 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta13-28
74      peptide with carboxyl terminal Cys residue
75      inserted and two added Gly residues
76 <220> FEATURE:
77 <221> NAME/KEY: MOD_RES
78 <222> LOCATION: (1)
79 <223> OTHER INFORMATION: Xaa = acetyl histidine
80 <400> SEQUENCE: 5
W--> 81      Xaa His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
82          1             5             10             15
83      Gly Gly Cys

```

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/724,552

DATE: 01/27/2003
TIME: 09:35:57

Input Set : N:\Crf3\RULE60\09724552.raw.txt
Output Set: N:\CRF4\01272003\I724552.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:4; Xaa Pos. 2
Seq#:5; Xaa Pos. 1

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/724,552

DATE: 01/27/2003

TIME: 09:35:57

Input Set : N:\Crf3\RULE60\09724552.raw.txt

Output Set: N:\CRF4\01272003\I724552.raw

L:65 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:0
L:81 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:0